BBA24
antibody from R&D Systems
Targeting: SELL
CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR
Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BBA24 - Provider product page
- Provider
- R&D Systems
- Product name
- Human L-Selectin/CD62L Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Binds to CHO cells expressing the human L-Selectin/CD62L protein. It does not recognize CHO cells expressing either the human E-Selectin or human P-Selectin.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 4G8
- Vial size
- 200 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Augmentation of Human Monocyte Responses to Lipopolysaccharide by the Protein S and Mer/Tyro3 Receptor Tyrosine Kinase Axis.
NFKB1 regulates human NK cell maturation and effector functions.
Regulatory T cells inhibit CD34+ cell differentiation into NK cells by blocking their proliferation.
Facile supermolecular aptamer inhibitors of L-selectin.
Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.
Aberration of CCR7 CD8 memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4 T cells.
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
Barth ND, Marwick JA, Heeb MJ, Gale AJ, Rossi AG, Dransfield I
Journal of immunology (Baltimore, Md. : 1950) 2018 Nov 1;201(9):2602-2611
Journal of immunology (Baltimore, Md. : 1950) 2018 Nov 1;201(9):2602-2611
NFKB1 regulates human NK cell maturation and effector functions.
Lougaris V, Patrizi O, Baronio M, Tabellini G, Tampella G, Damiati E, Frede N, van der Meer JWM, Fliegauf M, Grimbacher B, Parolini S, Plebani A
Clinical immunology (Orlando, Fla.) 2017 Feb;175:99-108
Clinical immunology (Orlando, Fla.) 2017 Feb;175:99-108
Regulatory T cells inhibit CD34+ cell differentiation into NK cells by blocking their proliferation.
Pedroza-Pacheco I, Shah D, Domogala A, Luevano M, Blundell M, Jackson N, Thrasher A, Madrigal A, Saudemont A
Scientific reports 2016 Feb 26;6:22097
Scientific reports 2016 Feb 26;6:22097
Facile supermolecular aptamer inhibitors of L-selectin.
Chang EK, Eckert MA, Ali MM, Riazifar H, Pone EJ, Liu L, Zhao W
PloS one 2015;10(3):e0123034
PloS one 2015;10(3):e0123034
Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.
Zhang Y, Patel B, Dey A, Ghorani E, Rai L, Elham M, Castleton AZ, Fielding AK
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 1;188(3):1002-10
Journal of immunology (Baltimore, Md. : 1950) 2012 Feb 1;188(3):1002-10
Aberration of CCR7 CD8 memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4 T cells.
Sen Y, Chunsong H, Baojun H, Linjie Z, Qun L, San J, Qiuping Z, Junyan L, Zhang X, Jinquan T
Immunology 2004 Jun;112(2):274-89
Immunology 2004 Jun;112(2):274-89
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
Smith DE, Hanna R, Della Friend, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE
Immunity 2003 Jan;18(1):87-96
Immunity 2003 Jan;18(1):87-96
The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
Smith DE, Hanna R, Della Friend, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE
Immunity 2003 Jan;18(1):87-96
Immunity 2003 Jan;18(1):87-96
No comments: Submit comment
No validations: Submit validation data